← Back to Search

Monoclonal Antibodies

ANX005 for Huntington's Disease

Phase 2
Waitlist Available
Led By Rajeev Kumar, MD
Research Sponsored by Annexon, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to week 36
Awards & highlights

Study Summary

This study is evaluating whether a drug may help reduce symptoms of Huntington's disease.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to week 36
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to week 36 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Pharmacodynamics (PD) effects of ANX005
Pharmacokinetics (PK) of ANX005
Safety and tolerability of intravenous ANX005 administered for up to 22 weeks in subjects with, or at risk for, manifest Huntington's Disease
Other outcome measures
Exploratory effects of ANX005 on measures of efficacy

Trial Design

1Treatment groups
Experimental Treatment
Group I: ANX005Experimental Treatment1 Intervention
IV
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
ANX005
2020
Completed Phase 2
~50

Find a Location

Who is running the clinical trial?

Annexon, Inc.Lead Sponsor
12 Previous Clinical Trials
770 Total Patients Enrolled
Rajeev Kumar, MDPrincipal InvestigatorRocky Mountain Movement Disorders Center, Englewood, CO
2 Previous Clinical Trials
118 Total Patients Enrolled
Benjamin Hoehn, MDStudy DirectorAnnexon, Inc.
2 Previous Clinical Trials
127 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
An Open Label Study of ANX005 in Subjects With, or at Risk for, Manifest Huntington's Disease
2020. "An Open Label Study of ANX005 in Subjects With, or at Risk for, Manifest Huntington's Disease". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04514367.
~6 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top